多机构实施下颌下腺转位的可行性与治疗时间研究
多机构研究评估49例接受下颌下腺转位(SMGT)患者的可行性及治疗延迟发生率,从诊断到主要治疗中位时间42天,从手术到辅助治疗中位时间33天,7/49例(14%)出现治疗延迟,6例术后放疗延迟(6/19;32%),认为适当协调下SMGT可纳入临床路径而不增加治疗延迟。
要点
- 49例SMGT患者中,从诊断到主要治疗中位时间42天(IQR 32-54天)。
- 从手术到辅助治疗中位时间33天(IQR 28-47天)。
- 7/49例(14%)出现治疗延迟,6例术后放疗延迟(6/19;32%)。
核心结论
- 在适当医疗协调下,SMGT可纳入临床路径,目标为减少放射性口干而不增加治疗延迟。
研究设计与样本
- 多机构可行性研究,纳入49例接受下颌下腺转位(SMGT)的患者,提取诊断及关键治疗事件时间点,治疗延迟定义为从诊断到根治性治疗>60天或手术后到辅助治疗>6周。
主要发现
- 从诊断到主要治疗中位时间42天(IQR,32-54天)。
- 从手术到辅助治疗中位时间33天(IQR,28-47天)。
- 7/49例(14%)出现开始治疗延迟。
- 6例出现术后放疗延迟(6/19;32%)。
临床怎么用
- 原文结论认为在适当医疗协调下,SMGT可纳入临床路径,目标为减少放射性口干而不增加治疗延迟。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Submandibular gland transfer (SMGT) mitigates radiation-induced xerostomia but has yet to be widely adopted. We evaluate the feasibility of incorporating SMGT at multiple academic institutions and report the incidence of treatment delay. METHODS: Forty-nine patients were identified who underwent SMGT. Time points pertaining to diagnosis and key treatment events including SMGT, surgery, chemotherapy, and radiation were extracted. Treatment delay was defined as either >60 days from diagnosis to definitive therapy or >6 weeks between surgery and adjuvant therapy. RESULTS: Median time from diagnosis to primary treatment was 42 days (IQR, 32-54). Median time from surgery to adjuvant therapy was 33 days (IQR, 28-47). Delay in starting treatment was observed in 7/49 patients (14%). Six patients incurred a delay in postoperative radiation therapy (6/19; 32%). CONCLUSIONS: With appropriate care coordination, SMGT can be implemented into a clinical pathway with a goal of decreasing radiation-induced xerostomia without increasing treatment delays.
引用
- Pang J, Ching HH, Sobel RH, et al. Implementation of submandibular gland transfer: A multi-institutional study of feasibility and time to treatment. Head Neck. 2019. PMID: 30723965. doi:10.1002/hed.25685
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。